Novo Nordisk A/S

New Study Shows Different Perceptions of Control Among Physicians and Patients May Lead to Suboptimal Type 2 Diabetes Management

Stockholm, Sweden (ots/PRNewswire) - Results presented today at the European Association for the Study of Diabetes (EASD) showed that increased awareness about how patients' and physicians' perceptions of control differ, could benefit physician-patient communication and improve diabetes management.[1] New findings from the Perceptions of Control (POC) study showed adults with type 2 diabetes uncontrolled on basal insulin had a broader definition of control, perceived greater obstacles to maintaining control and that life was impacted significantly more than physicians expected.[1]

To view the Multimedia News Release, please click:

"There is a significant gap in perceptions of control between physicians and patients in how they define control, the obstacles and how being uncontrolled on basal insulin impacts patients' daily lives," said Meryl Brod, PhD, lead investigator of the POC research study. "Having a more open dialogue during consultations may provide more insight into these critical factors which could improve diabetes management and lead to more effective individualised treatment plans."

The study identified that physicians defined control in measurable, clinical terms such as frequency/severity of hypoglycaemia (93% vs 69%, p<0.001), complications (89% vs 75%, p<0.001) and HbA1c (85% vs 79%, p<0.05) versus patients uncontrolled on basal insulin respectively.[1] Although these clinical measures were important to people with type 2 diabetes, their definitions of control had a much broader focus than physicians and included the amount of insulin (units) taken per day (78% vs 29%, p<0.001), energy levels (75% vs 33%, p<0.001) and how much they have to think about their disease (68% vs 31%, p<0.001) amongst other factors.[1]

People with type 2 diabetes uncontrolled on basal insulin perceived more obstacles to achieving control compared to physicians, including stress (75% vs 54%, p<0.001), medicine side-effects (70% vs 56%, p<0.001) and a lack of patient support groups (56% vs 11%, p<0.001).[1]

The impact of being uncontrolled on basal insulin and how it interfered in one's life was perceived as significantly greater than physicians believed including aspects such as mood/emotions (63% vs 33%, p<0.001), making plans (62% vs 16%, p<0.001) and how much one accomplished during the day (62% vs 23% p<0.001) amongst other factors.[1]

About the Perception of Control (POC) Study 

The POC study was based on information collected from a web survey of 300 physicians and 1,012 adults with type 2 diabetes uncontrolled on basal insulin (physician-confirmed HbA1c> 8% (64 mmol/mol)) from the UK (n=100 physicians and 620 patients), Sweden (n=100 physicians and 240 patients) and Switzerland (n=100 physicians and 152 patients).[1] Information was also collected from a control group of 295 adults with type 2 diabetes controlled on basal insulin (physician-confirmed HbA1c <7.5% (59 mmol/mol) from the UK.[1] In total, data were collected from 1,607 patients and physicians for analysis. The purpose of the study was to investigate how this patient population perceived control and whether it differed from perceptions of control among physicians.[1]  

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries. For more information, visit [], Facebook [], Twitter [], LinkedIn [], YouTube []

Further Information 
Katrine Sperling 
Asa Josefsson 
Peter Hugreffe Ankersen 
Melanie Raouzeos 
Daniel Bohsen 
Frank Daniel Mersebach (US) 



1) Brod M, et al. Perceptions of diabetes control among physicians and patients with
  uncontrolled type 2 diabetes using basal insulin. Poster presentation (#890) at the
  51st European Association for the Study of Diabetes (EASD) Annual Meeting, 16
  September 2015.


Original-Content von: Novo Nordisk A/S, übermittelt durch news aktuell

Weitere Meldungen: Novo Nordisk A/S

Das könnte Sie auch interessieren: